MD20140119A2 - Agenţi pentru tratarea afecţiunilor care implică modularea receptorilor de rianodină - Google Patents
Agenţi pentru tratarea afecţiunilor care implică modularea receptorilor de rianodină Download PDFInfo
- Publication number
- MD20140119A2 MD20140119A2 MD20140119A MD20140119A MD20140119A2 MD 20140119 A2 MD20140119 A2 MD 20140119A2 MD 20140119 A MD20140119 A MD 20140119A MD 20140119 A MD20140119 A MD 20140119A MD 20140119 A2 MD20140119 A2 MD 20140119A2
- Authority
- MD
- Moldova
- Prior art keywords
- treatment
- modulation
- ryanodine receptors
- disorders caused
- ryrs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/841—Muscles; heart
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
Abstract
Prezenta invenţie se referă la derivaţi ai 1,4-benzotiazepinei reprezentaţi prin formula structurală (I):(I)unde R este COOH, şi la sărurile acceptabile farmaceutic ale acestora.Se descrie utilizarea compuşilor menţionaţi pentru tratarea stărilor, tulburărilor şi a bolilor asociate cu receptorii rianodinei (RyRs), care reglează funcţionarea canalelor de calciu în celule.Invenţia dezvăluie, de asemenea, compoziţii farmaceutice care conţin compuşii descrişi şi utilizarea acestora pentru tratarea bolilor şi a stărilor asociate cu RyRs, în special a tulburărilor sistemului cardiac, osteomuscular şi nervos central.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625890P | 2012-04-18 | 2012-04-18 | |
| EP12167732.2A EP2708535A1 (en) | 2012-05-11 | 2012-05-11 | Agents for treating disorders involving modulation of ryanodine receptors |
| PCT/EP2013/057958 WO2013156505A1 (en) | 2012-04-18 | 2013-04-17 | Agents for treating disorders involving modulation of ryanodine receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MD20140119A2 true MD20140119A2 (ro) | 2015-04-30 |
| MD4489B1 MD4489B1 (ro) | 2017-06-30 |
| MD4489C1 MD4489C1 (ro) | 2018-01-31 |
Family
ID=49165460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20140119A MD4489C1 (ro) | 2012-04-18 | 2013-04-17 | Derivaţi de 1,4-benzotiazepină, procedeu de sinteză a lor, compoziţii farmaceutice care le conţin şi utilizarea acestora pentru tratarea sau prevenirea afecţiunilor care implică modularea receptorilor de rianodină |
Country Status (48)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016514685A (ja) | 2013-03-15 | 2016-05-23 | ロザリンド フランクリン ユニバーシティー オブ メディスン アンド サイエンス | 異常レベルのカルシウム放出からリアノジン受容体を安定化するための化合物 |
| US9725429B2 (en) | 2013-03-15 | 2017-08-08 | Rosalind Franklin University Of Medicine And Science | Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| ES2976212T3 (es) | 2013-07-18 | 2024-07-26 | Baylor College Medicine | Métodos y composiciones para el tratamiento de la atrofia muscular, la debilidad muscular y/o la caquexia |
| WO2015197562A1 (en) * | 2014-06-23 | 2015-12-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of disorders or diseases associated with ryanodine receptor dysfunction |
| CN106795148B (zh) | 2014-07-30 | 2019-12-10 | 埃塔斯制药株式会社 | 1,4-苯并硫氮杂*-1-氧化物衍生物的光学异构体及使用它的医药组合物 |
| WO2016109596A1 (en) * | 2014-12-30 | 2016-07-07 | Myotherix, Inc. | Novel calcium modulators |
| ES2643856B1 (es) | 2016-05-24 | 2018-08-03 | Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea | Triazoles para la regulación de la homeostasis de calcio intracelular |
| US11426415B2 (en) | 2017-03-06 | 2022-08-30 | Washington University | Treatment for Wolfram syndrome and other endoplasmic reticulum stress disorders |
| JP7282332B2 (ja) * | 2017-10-25 | 2023-05-29 | 学校法人順天堂 | リアノジン受容体阻害薬 |
| PL3773537T3 (pl) | 2018-04-19 | 2022-05-23 | Tvardi Therapeutics, Inc. | Inhibitory stat3 |
| US11026905B2 (en) | 2018-04-19 | 2021-06-08 | Tvardi Therapeutics, Inc. | STAT3 inhibitors |
| AU2021209679A1 (en) | 2020-01-24 | 2022-06-16 | Tvardi Therapeutics, Inc. | Therapeutic compounds, formulations, and uses thereof |
| JP7825618B2 (ja) * | 2020-11-06 | 2026-03-06 | サイトキネティックス， インコーポレイテッド | 二環式１，４－ジアゼパノン及びその治療的使用 |
| JP2024503045A (ja) | 2021-01-08 | 2024-01-24 | アームゴ・ファーマ・インコーポレーテッド | リアノジン受容体調節因子の結晶形態およびその使用 |
| CN115369163A (zh) * | 2021-05-17 | 2022-11-22 | 中国科学院上海营养与健康研究所 | Ryr2及其下调剂在治疗转移性结直肠癌中的应用 |
| BR112023024170A2 (pt) * | 2021-05-20 | 2024-02-06 | Armgo Pharma Inc | Composições farmacêuticas compreendendo um modulador do receptor da rianodina e usos das mesmas |
| WO2022246114A2 (en) * | 2021-05-20 | 2022-11-24 | Armgo Pharma, Inc. | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof |
| EP4433062A4 (en) * | 2021-11-16 | 2025-10-22 | Rycarma Therapeutics Inc | THERAPEUTIC COMPOUNDS |
| US20230302013A1 (en) * | 2022-02-09 | 2023-09-28 | The Trustees Of Columbia University In The City Of New York | METHOD OF TREATING VIRAL-INDUCED COGNITIVE DYSFUNCTION BY TARGETING LEAKY RyR2 CHANNELS |
| EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
| IL317006A (en) | 2022-06-15 | 2025-01-01 | Tvardi Therapeutics Inc | Prodrugs of 3STAT inhibitors |
| EP4548971A1 (en) * | 2023-11-06 | 2025-05-07 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | 1,4-benzothiazepines and related compounds with cyclopropanol groups as multi-targeted drugs |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368063B1 (de) * | 1988-11-05 | 1992-06-10 | Bayer Ag | Verfahren zur Kernchlorierung von aromatischen Kohlenwasserstoffen |
| GB9021813D0 (en) * | 1990-10-08 | 1990-11-21 | Ici Plc | Tricyclic heterocycles |
| EP0593603B1 (en) | 1991-06-28 | 2002-11-20 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
| RU2115650C1 (ru) * | 1992-11-09 | 1998-07-20 | Дзе Бутс Компани ПЛС | 2,3,4,5-тетрагидро-1,4-бензотиазепины, их стереоизомеры или их фармацевтически приемлемые соли, способ их получения, фармацевтическая композиция, обладающая противосудорожным действием |
| FR2752017B1 (fr) | 1996-08-01 | 1998-10-16 | Hispano Suiza Sa | Inverseur de poussee de turboreacteur a portes formant ecopes |
| GB9914745D0 (en) | 1999-06-24 | 1999-08-25 | Knoll Ag | Therapeutic agents |
| US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| US8022058B2 (en) * | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| DK1392291T3 (da) | 2000-10-30 | 2007-10-08 | Janssen Pharmaceutica Nv | Tripeptidylpeptidaseinhibitorer |
| US7544678B2 (en) | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| JP2007525165A (ja) | 2003-03-07 | 2007-09-06 | トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | タイプ１ライアノジン受容体に基づく方法 |
| US20090292119A1 (en) * | 2003-10-07 | 2009-11-26 | The Trustees Of Columbia University In The City Of New York | Methods for synthesizing benzothiazepine compounds |
| DE112005003511T5 (de) | 2005-03-23 | 2008-04-17 | Battelle Memorial Institute, Richland | RFID-System mit verbesserter Leistungsfähigkeit |
| US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| WO2007127145A2 (en) | 2006-04-25 | 2007-11-08 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of cardiac arrhythmia in non-human animals |
| WO2008060332A2 (en) | 2006-06-02 | 2008-05-22 | The Trustees Of Columbia University In The City Of New York | Methods for treating or reducing muscle fatigue |
| WO2008021439A2 (en) * | 2006-08-17 | 2008-02-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treatment of cardiac hypertrophy |
| WO2008021432A2 (en) | 2006-08-17 | 2008-02-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treatment of conditions affecting the nervous system |
| WO2008064264A2 (en) | 2006-11-20 | 2008-05-29 | Armgo Pharma, Inc. | In vivo methods for identifying and screening compounds that modulate calstabin binding to a ryanodine receptor |
| CA2717523C (en) * | 2008-03-03 | 2014-01-21 | Armgo Pharma, Inc. | Process for preparing benzothiazepines from .gamma.-aminoalkylbenzenes |
| CN101891706B (zh) * | 2010-04-09 | 2013-05-29 | 复旦大学 | 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途 |
| WO2012019071A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating sarcopenia |
| WO2012019076A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury |
| WO2012037105A1 (en) | 2010-09-14 | 2012-03-22 | The Trustees Of Columbia University In The City Of New York | Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases |
-
2012
- 2012-05-11 EP EP12167732.2A patent/EP2708535A1/en not_active Withdrawn
-
2013
- 2013-04-09 JO JOP/2013/0090A patent/JO3070B1/ar active
- 2013-04-12 UY UY0001034742A patent/UY34742A/es not_active Application Discontinuation
- 2013-04-17 TW TW102113668A patent/TWI507399B/zh active
- 2013-04-17 AP AP2014008011A patent/AP3591A/xx active
- 2013-04-17 RU RU2014145939A patent/RU2644350C2/ru not_active IP Right Cessation
- 2013-04-17 PT PT131640518T patent/PT2653466E/pt unknown
- 2013-04-17 MX MX2014012575A patent/MX350890B/es active IP Right Grant
- 2013-04-17 EA EA201401141A patent/EA027922B1/ru not_active IP Right Cessation
- 2013-04-17 ES ES13164051.8T patent/ES2529890T3/es active Active
- 2013-04-17 MD MDA20140119A patent/MD4489C1/ro not_active IP Right Cessation
- 2013-04-17 ME MEP-2014-147A patent/ME01969B/me unknown
- 2013-04-17 AR ARP130101246A patent/AR090712A1/es unknown
- 2013-04-17 SG SG11201406404YA patent/SG11201406404YA/en unknown
- 2013-04-17 SA SA113340479A patent/SA113340479B1/ar unknown
- 2013-04-17 RS RS20140701A patent/RS53711B1/sr unknown
- 2013-04-17 KR KR1020147032345A patent/KR101731459B1/ko active Active
- 2013-04-17 JP JP2015506221A patent/JP5965542B2/ja active Active
- 2013-04-17 CU CUP2014000119A patent/CU24327B1/es unknown
- 2013-04-17 BR BR112014025670-5A patent/BR112014025670B1/pt active IP Right Grant
- 2013-04-17 UA UAA201412301A patent/UA113759C2/uk unknown
- 2013-04-17 SI SI201330014T patent/SI2653466T1/sl unknown
- 2013-04-17 DK DK13164051.8T patent/DK2653466T3/en active
- 2013-04-17 HU HUE13164051A patent/HUE024284T2/en unknown
- 2013-04-17 PE PE2014001612A patent/PE20142193A1/es active IP Right Grant
- 2013-04-17 CN CN201380030477.8A patent/CN104350045B/zh active Active
- 2013-04-17 EP EP20130164051 patent/EP2653466B1/en active Active
- 2013-04-17 MY MYPI2014702980A patent/MY167783A/en unknown
- 2013-04-17 AU AU2013248313A patent/AU2013248313B2/en active Active
- 2013-04-17 GE GEAP201713636A patent/GEP20186836B/en unknown
- 2013-04-17 CA CA2870599A patent/CA2870599C/en active Active
- 2013-04-17 NZ NZ701122A patent/NZ701122A/en unknown
- 2013-04-17 WO PCT/EP2013/057958 patent/WO2013156505A1/en not_active Ceased
- 2013-04-17 PL PL13164051T patent/PL2653466T3/pl unknown
- 2013-04-18 US US13/865,359 patent/US20130281512A1/en not_active Abandoned
- 2013-11-11 US US14/076,474 patent/US8853198B2/en active Active
-
2014
- 2014-09-03 US US14/475,980 patent/US20140378437A1/en not_active Abandoned
- 2014-10-07 IL IL235043A patent/IL235043A/en active IP Right Grant
- 2014-10-07 PH PH12014502256A patent/PH12014502256B1/en unknown
- 2014-10-10 TN TN2014000424A patent/TN2014000424A1/fr unknown
- 2014-10-10 CO CO14224913A patent/CO7091184A2/es active IP Right Grant
- 2014-10-13 DO DO2014000230A patent/DOP2014000230A/es unknown
- 2014-10-14 CR CR20140476A patent/CR20140476A/es unknown
- 2014-10-14 CL CL2014002756A patent/CL2014002756A1/es unknown
- 2014-10-15 ZA ZA2014/07499A patent/ZA201407499B/en unknown
- 2014-10-17 GT GT201400222A patent/GT201400222A/es unknown
- 2014-10-30 NI NI201400123A patent/NI201400123A/es unknown
- 2014-11-13 MA MA37525A patent/MA37525B1/fr unknown
- 2014-11-17 EC ECIEPI201427564A patent/ECSP14027564A/es unknown
- 2014-11-18 HR HRP20141113TT patent/HRP20141113T8/hr unknown
- 2014-12-17 CY CY20141101052T patent/CY1115826T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD20140119A2 (ro) | Agenţi pentru tratarea afecţiunilor care implică modularea receptorilor de rianodină | |
| EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
| EA201490774A1 (ru) | Новые производные оксазина и их применение при лечении заболевания | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| DOP2016000276A (es) | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
| GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
| EA201492281A1 (ru) | Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| EA201492285A1 (ru) | Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar) | |
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| EA201591195A1 (ru) | Новые хинолоновые производные | |
| UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
| EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| UY33278A (es) | Pirimidinas sustituidas como antagonistas del receptor de la protaglandina d2 | |
| EA201792071A3 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
| CO2017003305A2 (es) | Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa | |
| PE20150629A1 (es) | Derivados de etinilo como moduladores de la actividad del receptor de mglur5 | |
| EA201300389A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| EA201001566A1 (ru) | Новый класс спиропиперидинов для лечения нейродегенеративных заболеваний | |
| PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| EA201390398A1 (ru) | Арилсульфонамиды для лечения заболеваний цнс | |
| WO2014014794A3 (en) | Mineralocorticoid receptor antagonists | |
| EA201590722A1 (ru) | Производные этинила в качестве модуляторов активности метаботропного глутаматного рецептора подтипа 5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HA9A | Change of inventorship in application (patent for invention) |
Free format text: FORMER INVENTORS: YAN JIAMING, US; BELVEDERE SANDRO, US; WEBB YAEL, US; BERTRAND MARC, FR; VILLENEUVE NICOLE, FR; 2 INVENTORS ARE ADDED Inventor name: MARKS ANDREW R., US Free format text: FORMER INVENTORS: YAN JIAMING, US; BELVEDERE SANDRO, US; WEBB YAEL, US; BERTRAND MARC, FR; VILLENEUVE NICOLE, FR; 2 INVENTORS ARE ADDED Inventor name: PEGLION JEAN-LOUIS, FR |
|
| FG4A | Patent for invention issued | ||
| KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
| MM4A | Patent for invention definitely lapsed due to non-payment of fees |